|
1
|
Bachelerie F, Ben-Baruch A, Burkhardt AM,
Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH,
Locati M, Luster AD, et al: International Union of Basic and
Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended
family of chemokine receptors and introducing a new nomenclature
for atypical chemokine receptors. Pharmacol Rev. 66:1–79. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S:
CXC chemokines and chemokine receptors in gastric cancer: From
basic findings towards therapeutic targeting. World J
Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee HJ and Jo DY: The role of the
CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
Histol Histopathol. 27:1155–1161. 2012.PubMed/NCBI
|
|
5
|
Libert F, Parmentier M, Lefort A, Dumont
JE and Vassart G: Complete nucleotide sequence of a putative G
protein coupled receptor: RDC1. Nucleic Acids Res. 18:19171990.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sánchez-Martín L, Sánchez-Mateos P and
Cabañas C: CXCR7 impact on CXCL12 biology and disease. Trends Mol
Med. 19:12–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tarnowski M, Liu R, Wysoczynski M,
Ratajczak J, Kucia M and Ratajczak MZ: CXCR7: A new SDF-1-binding
receptor in contrast to normal CD34(+) progenitors is functional
and is expressed at higher level in human malignant hematopoietic
cells. Eur J Haematol. 85:472–483. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cole KE, Strick CA, Paradis TJ, Ogborne
KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, et
al: Interferon-inducible T cell alpha chemoattractant (I-TAC): A
novel non-ELR CXC chemokine with potent activity on activated T
cells through selective high affinity binding to CXCR3. J Exp Med.
187:2009–2021. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maksym RB, Tarnowski M, Grymula K,
Tarnowska J, Wysoczynski M, Liu R, Czerny B, Ratajczak J, Kucia M
and Ratajczak MZ: The role of stromal-derived factor-1 - CXCR7 axis
in development and cancer. Eur J Pharmacol. 625:31–40. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hartmann TN, Grabovsky V, Pasvolsky R,
Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M and
Alon R: A crosstalk between intracellular CXCR7 and CXCR4 involved
in rapid CXCL12-triggered integrin activation but not in
chemokine-triggered motility of human T lymphocytes and
CD34+ cells. J Leukoc Biol. 84:1130–1140. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Infantino S, Moepps B and Thelen M:
Expression and regulation of the orphan receptor RDC1 and its
putative ligand in human dendritic and B cells. J Immunol.
176:2197–2207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mazzinghi B, Ronconi E, Lazzeri E,
Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti
GS, Becherucci F, et al: Essential but differential role for CXCR4
and CXCR7 in the therapeutic homing of human renal progenitor
cells. J Exp Med. 205:479–490. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naumann U, Cameroni E, Pruenster M,
Mahabaleshwar H, Raz E, Zerwes HG, Rot A and Thelen M: CXCR7
functions as a scavenger for CXCL12 and CXCL11. PLoS One.
5:e91752010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
et al: A novel chemokine receptor for SDF-1 and I-TAC involved in
cell survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eva C and Sprengel R: A novel putative G
protein-coupled receptor highly expressed in lung and testis. DNA
Cell Biol. 12:393–399. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Libert F, Parmentier M, Lefort A, Dinsart
C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE and Vassart G:
Selective amplification and cloning of four new members of the G
protein-coupled receptor family. Science. 244:569–572. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tripathi V, Verma R, Dinda A, Malhotra N,
Kaur J and Luthra K: Differential expression of RDC1/CXCR7 in the
human placenta. J Clin Immunol. 29:379–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keeley EC, Mehrad B and Strieter RM: CXC
chemokines in cancer angiogenesis and metastases. Adv Cancer Res.
106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raggo C, Ruhl R, McAllister S, Koon H,
Dezube BJ, Früh K and Moses AV: Novel cellular genes essential for
transformation of endothelial cells by Kaposi's sarcoma-associated
herpesvirus. Cancer Res. 65:5084–5095. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miao Z, Luker KE, Summers BC, Berahovich
R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A,
Luker GD, et al: CXCR7 (RDC1) promotes breast and lung tumor growth
in vivo and is expressed on tumor-associated vasculature. Proc Natl
Acad Sci USA. 104:15735–15740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Shiozawa Y, Wang J, Wang Y, Jung
Y, Pienta KJ, Mehra R, Loberg R and Taichman RS: The role of
CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate
cancer. J Biol Chem. 283:4283–4294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berahovich RD, Zabel BA, Penfold ME, Lewén
S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, et al:
CXCR7 protein is not expressed on human or mouse leukocytes. J
Immunol. 185:5130–5139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bennani-Baiti IM, Cooper A, Lawlor ER,
Kauer M, Ban J, Aryee DN and Kovar H: Intercohort gene expression
co-analysis reveals chemokine receptors as prognostic indicators in
Ewing's sarcoma. Clin Cancer Res. 16:3769–3778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tarnowski M, Grymula K, Reca R, Jankowski
K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M and
Ratajczak MZ: Regulation of expression of stromal-derived factor-1
receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer
Res. 8:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Van Rechem C, Rood BR, Touka M, Pinte S,
Jenal M, Guérardel C, Ramsey K, Monté D, Bégue A, Tschan MP, et al:
Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct
target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem.
284:20927–20935. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Calatozzolo C, Canazza A, Pollo B, Di
Pierro E, Ciusani E, Maderna E, Salce E, Sponza V, Frigerio S, Di
Meco F, et al: Expression of the new CXCL12 receptor, CXCR7, in
gliomas. Cancer Biol Ther. 11:242–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hattermann K, Held-Feindt J, Lucius R,
Müerköster SS, Penfold ME, Schall TJ and Mentlein R: The chemokine
receptor CXCR7 is highly expressed in human glioma cells and
mediates antiapoptotic effects. Cancer Res. 70:3299–3308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mehra R, Serebriiskii IG, Burtness B,
Astsaturov I and Golemis EA: Aurora kinases in head and neck
cancer. Lancet Oncol. 14:e425–e435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miyazaki H, Takabe K and Yeudall WA:
Chemokines, chemokine receptors and the gastrointestinal system.
World J Gastroenterol. 19:2847–2863. 2013.PubMed/NCBI
|
|
31
|
Yeudall WA and Miyazaki H: Chemokines and
squamous cancer of the head and neck: Targets for therapeutic
intervention? Expert Rev Anticancer Ther. 7:351–360. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia J, Wang J, Chen N, Dai Y, Hong Y, Chen
X and Cheng B: Expressions of CXCR7/ligands may be involved in oral
carcinogenesis. J Mol Histol. 42:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maussang D, Mujić-Delić A, Descamps FJ,
Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF,
van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al: Llama-derived
single variable domains (nanobodies) directed against chemokine
receptor CXCR7 reduce head and neck cancer cell growth in vivo. J
Biol Chem. 288:29562–29572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY,
Xue WQ, Chen YB, Zhang Y and Jia WH: HOTAIR, a prognostic factor in
esophageal squamous cell carcinoma, inhibits WIF-1 expression and
activates Wnt pathway. Cancer Sci. 104:1675–1682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tachezy M, Zander H, Gebauer F, von Loga
K, Pantel K, Izbicki JR and Bockhorn M: CXCR7 expression in
esophageal cancer. J Transl Med. 11:2382013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iwakiri S, Mino N, Takahashi T, Sonobe M,
Nagai S, Okubo K, Wada H, Date H and Miyahara R: Higher expression
of chemokine receptor CXCR7 is linked to early and metastatic
recurrence in pathological stage I nonsmall cell lung cancer.
Cancer. 115:2580–2593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhi Y, Chen J, Zhang S, Chang X, Ma J and
Dai D: Down-regulation of CXCL12 by DNA hypermethylation and its
involvement in gastric cancer metastatic progression. Dig Dis Sci.
57:650–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y,
Pan M, Wu Y, Zhang C and Zhang Y: Alteration of CXCR7 expression
mediated by TLR4 promotes tumor cell proliferation and migration in
human colorectal carcinoma. PLoS One. 6:e273992011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guillemot E, Karimdjee-Soilihi B, Pradelli
E, Benchetrit M, Goguet-Surmenian E, Millet MA, Larbret F, Michiels
JF, Birnbaum D, Alemanno P, et al: CXCR7 receptors facilitate the
progression of colon carcinoma within lung not within liver. Br J
Cancer. 107:1944–1949. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Romain B, Hachet-Haas M, Rohr S, Brigand
C, Galzi JL, Gaub MP, Pencreach E and Guenot D: Hypoxia
differentially regulated CXCR4 and CXCR7 signaling in colon cancer.
Mol Cancer. 13:582014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rupertus K, Sinistra J, Scheuer C, Nickels
RM, Schilling MK, Menger MD and Kollmar O: Interaction of the
chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of
tumor angiogenesis of colorectal cancer. Clin Exp Metastasis.
31:447–459. 2014. View Article : Google Scholar
|
|
42
|
Heckmann D, Maier P, Laufs S, Li L,
Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S, et
al: The disparate twins: A comparative study of CXCR4 and CXCR7 in
SDF-1α -induced gene expression, invasion and chemosensitivity of
colon cancer. Clin Cancer Res. 20:604–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
D'Alterio C, Avallone A, Tatangelo F,
Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno
C, Bianco F, et al: A prognostic model comprising pT stage, N
status, and the chemokine receptors CXCR4 and CXCR7 powerfully
predicts outcome in neoadjuvant resistant rectal cancer patients.
Int J Cancer. 135:379–390. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kheirelseid EA, Miller N, Chang KH, Nugent
M and Kerin MJ: Clinical applications of gene expression in
colorectal cancer. J Gastrointest Oncol. 4:144–157. 2013.PubMed/NCBI
|
|
45
|
Wang L, Zhang X, Jia LT, Hu SJ, Zhao J,
Yang JD, Wen WH, Wang Z, Wang T, Zhao J, et al: c-Myc-mediated
epigenetic silencing of MicroRNA-101 contributes to dysregulation
of multiple pathways in hepatocellular carcinoma. Hepatology.
59:1850–1863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xue TC, Chen RX, Han D, Chen J, Xue Q, Gao
DM, Sun RX, Tang ZY and Ye SL: Down-regulation of CXCR7 inhibits
the growth and lung metastasis of human hepatocellular carcinoma
cells with highly metastatic potential. Exp Ther Med. 3:117–123.
2012.PubMed/NCBI
|
|
47
|
Xue TC, Han D, Chen RX, Zou JH, Wang Y,
Tang ZY and Ye SL: High expression of CXCR7 combined with Alpha
fetoprotein in hepatocellular carcinoma correlates with
extra-hepatic metastasis to lung after hepatectomy. Asian Pac J
Cancer Prev. 12:657–663. 2011.PubMed/NCBI
|
|
48
|
Zheng K, Li HY, Su XL, Wang XY, Tian T, Li
F and Ren GS: Chemokine receptor CXCR7 regulates the invasion,
angiogenesis and tumor growth of human hepatocellular carcinoma
cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Monnier J, Boissan M, L'Helgoualc'h A,
Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C
and Samson M: CXCR7 is up-regulated in human and murine
hepatocellular carcinoma and is specifically expressed by
endothelial cells. Eur J Cancer. 48:138–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ghanem I, Riveiro ME, Paradis V, Faivre S,
de Parga PM and Raymond E: Insights on the CXCL12-CXCR4 axis in
hepatocellular carcinoma carcinogenesis. Am J Transl Res.
6:340–352. 2014.PubMed/NCBI
|
|
51
|
Xue TC, Jia QA, Bu Y, Chen RX, Cui JF,
Tang ZY and Ye SL: CXCR7 correlates with the differentiation of
hepatocellular carcinoma and suppresses HNF4α expression through
the ERK pathway. Oncol Rep. 32:2387–2396. 2014.PubMed/NCBI
|
|
52
|
Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY
and Ye SL: Transmembrane receptor CXCR7 increases the risk of
extrahepatic metastasis of relatively well-differentiated
hepatocellular carcinoma through upregulation of osteopontin. Oncol
Rep. 30:105–110. 2013.PubMed/NCBI
|
|
53
|
Hong TS, Ryan DP, Borger DR, Blaszkowsky
LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY,
Boucher Y, et al: A phase 1/2 and biomarker study of preoperative
short course chemoradiation with proton beam therapy and
capecitabine followed by early surgery for resectable pancreatic
ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 89:830–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Heinrich EL, Lee W, Lu J, Lowy AM and Kim
J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated
signaling pathways in pancreatic cancer cells. J Transl Med.
10:682012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guo JC, Li J, Yang YC, Zhou L, Zhang TP
and Zhao YP: Oligonucleotide microarray identifies genes
differentially expressed during tumorigenesis of DMBA-induced
pancreatic cancer in rats. PLoS One. 8:e829102013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gebauer F, Tachezy M, Effenberger K, von
Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR and
Bockhorn M: Prognostic impact of CXCR4 and CXCR7 expression in
pancreatic adenocarcinoma. J Surg Oncol. 104:140–145. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Weekes CD, Song D, Arcaroli J, Wilson LA,
Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn
RA and Hidalgo M: Stromal cell-derived factor 1α mediates
resistance to mTOR-directed therapy in pancreatic cancer.
Neoplasia. 14:690–701. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Roy I, Zimmerman NP, Mackinnon AC, Tsai S,
Evans DB and Dwinell MB: CXCL12 chemokine expression suppresses
human pancreatic cancer growth and metastasis. PLoS One.
9:e904002014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Maréchal R, Demetter P, Nagy N, Berton A,
Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van
Laethem JL: High expression of CXCR4 may predict poor survival in
resected pancreatic adenocarcinoma. Br J Cancer. 100:1444–1451.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yao X, Zhou L, Han S and Chen Y: High
expression of CXCR4 and CXCR7 predicts poor survival in gallbladder
cancer. J Int Med Res. 39:1253–1264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zabel BA, Wang Y, Lewén S, Berahovich RD,
Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, et al:
Elucidation of CXCR7-mediated signaling events and inhibition of
CXCR4-mediated tumor cell transendothelial migration by CXCR7
ligands. J Immunol. 183:3204–3211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luker KE, Gupta M and Luker GD: Imaging
chemokine receptor dimerization with firefly luciferase
complementation. FASEB J. 23:823–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Duda DG, Kozin SV, Kirkpatrick ND, Xu L,
Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway
inhibition: An emerging sensitizer for anticancer therapies? Clin
Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dai X, Xiong X, Wang L, Pan K, He L and Li
H: Effects of CXCR7-shRNA lentiviral vector on the growth and
invasiveness of human hepatoma carcinoma cells in vitro. Nan Fang
Yi Ke Da Xue Xue Bao. 33:994–998. 2013.(In Chinese). PubMed/NCBI
|
|
65
|
Ribas R, Ghazoui Z, Gao Q, Pancholi S,
Rani A, Dunbier A, Dowsett M and Martin LA: Identification of
chemokine receptors as potential modulators of endocrine resistance
in oestrogen receptor-positive breast cancers. Breast Cancer Res.
16:4472014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Walters MJ, Ebsworth K, Berahovich RD,
Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D,
Mulkearns-Hubert EE, et al: Inhibition of CXCR7 extends survival
following irradiation of brain tumours in mice and rats. Br J
Cancer. 110:1179–1188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hou KL, Hao MG, Bo JJ and Wang JH: CXCR7
in tumorigenesis and progression. Chin J Cancer. 29:456–459. 2010.
View Article : Google Scholar : PubMed/NCBI
|
